Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P61236
UPID:
YPEL3_HUMAN
Alternative names:
-
Alternative UPACC:
P61236; Q65Z99; Q86VK6; Q9BSJ4; Q9CQB6
Background:
Protein yippee-like 3 plays a crucial role in the regulation of cell proliferation and apoptosis among myeloid precursor cells. Its unique function positions it as a key player in hematopoiesis, the process responsible for the production of blood cells.
Therapeutic significance:
Understanding the role of Protein yippee-like 3 could open doors to potential therapeutic strategies. Its involvement in fundamental cellular processes suggests that targeting this protein could lead to innovative treatments for hematological disorders.